Table 3.
Pretreatment laboratory and clinical measures in sJIA. All patients presented with quotidian fever and rash.
| FSTL-1, ng/ml | Age, yrs | Cumulative Joint Count | WBC, 109/l | Hgb, g/dl | Platelet Count, 109/l | ESR, mm/h | CRP, mg/dl | sIL2-Rα, pg/ml | Ferritin, ng/ml | Medication Course† |
|---|---|---|---|---|---|---|---|---|---|---|
| 94 | 11 | 13 | 23.4 | 9 | 693 | 98 | 14.4 | 929.6 | 34 | 1 |
| 118 | 4 | 33 | 5.4 | 9.1 | 670 | 140 | NR | NR | 84 | 2 |
| 159 | 3 | 10 | 20.6 | 10.5 | 427 | 74 | NR | 2684 | 176 | 2 |
| 175 | 4 | 32 | 24.6 | NR | 314 | > 100 | 5.6 | 6934 | 9770 | 2†† |
| 176 | 14 | 13 | 27.4 | 11.2 | 521 | 115 | NR | 3385.6 | 869 | 2 |
| 176 | 3.5 | 3 | 8.3 | 10.6 | 519 | 34 | NR | 1020 | 39 | 1 |
| 177 | 2 | 4 | 27.6 | 10.1 | 631 | 50 | 1.4 | 587 | 10 | 1 |
| 187 | 5 | 13 | 18.5 | 9.4 | 677 | 109 | NR | 969.6 | 1102 | 2 |
| 218 | 3 | 5 | 12.9 | NR | 975 | 50 | NR | 3314 | NR | 2 |
| 222 | 4.5 | 2 | 19.9 | 7.6 | 364 | 140 | 18.9 | NR | 1541 | 1 |
| 242 | 4.5 | 9 | 44.5 | 10.7 | 924 | 140 | 20.5 | 7413 | 4109 | 2 |
| 248 | 11 | 13 | 21.1 | 9.6 | 539 | 140 | NR | NR | 4104 | 2 |
| 307 | 16 | 1 | 21.2 | NR | 325 | NR | NR | 5644 | 10200 | 3†† |
| 311 | 14 | 16 | 8.6 | 7.5 | 400 | 79 | 16.3 | NR | 2950 | 3†† |
| Average FSTL < 200 | 5.8 | 15.1 | 19.5 | 10.0 | 556.5 | 88.6 | 7.1 | 2358.6 | 1510.5 | — |
| Average FSTL > 200 | 8.8 | 7.7 | 21.4 | 8.9 | 587.8 | 109.8 | 18.6 | 5457.1 | 4580.8 | — |
| p value, FSTL > 200 vs < 200 | 0.297 | 0.144 | 0.756 | 0.250 | 0.814 | 0.398 | 0.085 | 0.098 | 0.141 | — |
†
Medication course: 1: NSAID; 2: methotrexate/biologic; 3: cyclosporine.
††
Developed MAS later in course. MAS: macrophage activation syndrome; NSAID: nonsteroidal antiinflammatory drugs; sJIA: systemic juvenile idiopathic arthritis; FSTL-1: Follistatin-like protein 1; WBC: white blood cells; Hgb: hemoglobin; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; sIL-2Rα: soluble interleukin-2 receptor-α; NR: not recorded.